Washington, DC (June 1, 2020) – Epstein Becker Green (EBG) is pleased to announce that Delia A. Deschaine, an attorney with significant U.S. Food and Drug Administration (FDA) and U.S. Drug Enforcement Administration (DEA) legal and compliance experience, has joined the firm in Washington, DC, from Hogan Lovells.
“The global pandemic has created opportunities for health care and life sciences companies to innovate; however, with that comes heightened regulatory obligations and potential scrutiny from enforcement agencies,” said George B. Breen, Chair of the firm’s National Health Care and Life Sciences Practice Steering Committee. “Now more than ever, these companies need experienced counsel to help guide them through the complex legal and compliance risk environment. Delia brings to us sought-after experience representing pharmaceutical, medical device, and biotechnology companies in FDA and DEA enforcement actions and litigation,” Breen added.
“We are fortunate to be adding Delia to our growing team, and we know that her experience defending clients in government enforcement actions, and knowing when it is appropriate to challenge potential unlawful government conduct, will add tremendous value to our clients during an unprecedented time,” added Mark E. Lutes, Chair of EBG’s Board of Directors.
Throughout her career, Ms. Deschaine has counseled clients through regulatory obligations under the federal Food, Drug, and Cosmetic Act and the Controlled Substances Act, including compliance with current Good Manufacturing Practices and the DEA’s expectations related to suspicious order monitoring, registration, recordkeeping, security, and reporting. Ms. Deschaine has also been recognized for her in-depth knowledge of cannabis-related regulations and developments, which will further strengthen the firm’s capabilities and work in that area. One of the earliest firm’s to formalize a cannabis law initiative, EBG has been successfully advising cannabis-related businesses and potential investors in those businesses, as well as ancillary-market companies, to help them understand the complicated matrix of federal, state, and local laws and regulations.
“I am thrilled to be joining the talented team at EBG and look forward to being a part of the focused platform that the firm offers,” said Ms. Deschaine. “The health care and life sciences industries face tremendous opportunities and challenges, and I cannot wait to bring all of my experience to the table to serve the firm’s outstanding clients,” she added.
Ms. Deschaine also previously served as an attorney at a boutique FDA regulatory law firm, where she represented pharmaceutical, medical device, and biotechnology companies in FDA and DEA enforcement actions and litigation. Earlier in her career, through the U.S. Attorney General’s Honors Program, she served as an Attorney Advisor for the DEA, where she received a Performance Award in 2011.
Over the past 12 months, EBG has increased its life sciences capabilities with several hires, including Julie Watson Lampley, Machelle Dunavant Shields, and Kathy Doelling in Tennessee, and Lauren Sullivan in Connecticut.
About Epstein Becker Green
Epstein Becker & Green, P.C., is a national law firm with a primary focus on health care and life sciences; employment, labor, and workforce management; and litigation and business disputes. Founded in 1973 as an industry-focused firm, Epstein Becker Green has decades of experience serving clients in health care, financial services, retail, hospitality, and technology, among other industries, representing entities from startups to Fortune 100 companies. Operating in locations throughout the United States and supporting domestic and multinational clients, the firm’s attorneys are committed to uncompromising client service and legal excellence. For more information, visit www.ebglaw.com.